Nature Communications (Apr 2023)

Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA

  • Mingyun Bae,
  • Gyuhee Kim,
  • Tae-Rim Lee,
  • Jin Mo Ahn,
  • Hyunwook Park,
  • Sook Ryun Park,
  • Ki Byung Song,
  • Eunsung Jun,
  • Dongryul Oh,
  • Jeong-Won Lee,
  • Young Sik Park,
  • Ki-Won Song,
  • Jeong-Sik Byeon,
  • Bo Hyun Kim,
  • Joo Hyuk Sohn,
  • Min Hwan Kim,
  • Gun Min Kim,
  • Eui Kyu Chie,
  • Hyun-Cheol Kang,
  • Sun-Young Kong,
  • Sang Myung Woo,
  • Jeong Eon Lee,
  • Jai Min Ryu,
  • Junnam Lee,
  • Dasom Kim,
  • Chang-Seok Ki,
  • Eun-Hae Cho,
  • Jung Kyoon Choi

DOI
https://doi.org/10.1038/s41467-023-37768-3
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Multi-cancer early detection remains a key challenge in cell-free DNA (cfDNA)-based liquid biopsy. Here, we perform cfDNA whole-genome sequencing to generate two test datasets covering 2125 patient samples of 9 cancer types and 1241 normal control samples, and also a reference dataset for background variant filtering based on 20,529 low-depth healthy samples. An external cfDNA dataset consisting of 208 cancer and 214 normal control samples is used for additional evaluation. Accuracy for cancer detection and tissue-of-origin localization is achieved using our algorithm, which incorporates cancer type-specific profiles of mutation distribution and chromatin organization in tumor tissues as model references. Our integrative model detects early-stage cancers, including those of pancreatic origin, with high sensitivity that is comparable to that of late-stage detection. Model interpretation reveals the contribution of cancer type-specific genomic and epigenomic features. Our methodologies may lay the groundwork for accurate cfDNA-based cancer diagnosis, especially at early stages.